all blindly following the NICE Guidance Notes. They are Guidance Notes but have to be blindly obeyed.
Just to balance this a little (NICE do get a lot of flak, and sometimes bring it on themselves).
NICE isn’t about bureaucracy for its own sake. It is an independent body charged with sifting all available published research evidence, alongside health economic data to establish whether an intervention works, is safe, and offers value for money.
So the more expensive something is, the more positive impact it must have on a person’s quality of life and health outcomes (including long-term health and diabetes-complications-avoidance).
The difficulty is that the last time T2 guidance was reviewed, there simply wasn’t the balance of evidence that “test strips for all T2s” was cost effective. There were a couple of big studies by Farmer et al that tried to see if people with T2 on non-hypo inducing meds got benefit from testing, but alas (partly because of the study protocol) they found that the majority didn’t like testing, got no clinical benefit, and actually found the numbers confusing/depressing when they
stuck to the diet they had been given.
Of course, that’s a different approach to many on the forum who use structured BG checks before and after meals in order to
change their diet to one that suits their body better.
But NICE’s job was to review the evidence, and make recommendations based on what it said (even if the clinicians were expecting or wanted something else).
CGM in T1 had exactly the same hurdle to get over. For years there wasn’t enough quality evidence that CGM worked well enough to excuse the cost (despite many people’s lived experience of how useful it was). That’s why I had to self fund (at £50 per sensor) until this year.
BG monitoring for T2s to fine tune diet needs more good quality evidence to tip the balance, unfortunately.